A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection in Patients With Locally Advanced or Metastatic Chordoma
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Izalontamab brengitecan (Primary)
- Indications Chordoma
- Focus Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
- 29 Jan 2025 New trial record